NTHINeOnc Technologies Holdings Inc.
NTHI
NeOnc Technologies Holdings Inc.164
Mkt Cap
$138.91MVolume
82,014.0052W High
$12.9952W Low
$3.20PE Ratio
-2.90NTHI Fundamentals
Price
$5.34Prev Close
$5.36Open
$5.3250D MA
$5.88Beta
0.00Avg. Volume
66,435.06EPS (Annual)
-$2.87P/B
-9.74Rev/Employee
$7,998.00$185.61
This Emerging Biotech Wave Could Create the Next Monster Healthcare Winners
The biotechnology sector continues attracting speculative capital as investors aggressively position around next-generation oncology, metabolic disease, and CNS therapy platforms. Artificial intelligence, precision medicine, RNA biology, and novel drug delivery technologies are rapidly reshaping how Wall Street evaluates emerging healthcare companies. As larger pharmaceutical companies race to secure pipeline assets and differentiated platforms, smaller clinical-stage companies with compelling preclinical or clinical data are increasingly finding themselves under the spotlight. $AKTX, $NTHI, $MTVA, $HCWB, $BAC, $STT, $BCS
The Biotech Repricing Wave May Be Starting as Capital Pours into High-Impact Oncology Platforms
Biotech investors are once again rotating aggressively into clinical-stage growth stories as a fresh wave of capital raises, pipeline expansions, analyst initiations, and oncology breakthroughs reshapes momentum across the sector. $NTHI, $IMMX, $RLAY, $AKTX, $LIMN
Clinical Catalysts Driving Momentum, Plus an Oldie and a Newie
Clinical catalysts are driving the market, this morning, plus a mover we’ve been covering for weeks and a new runner. $NTHI, $IMVT, $IBRX, $AMPG, $POET, $MWC
These Stocks are Riding Some of the Hottest Narratives on Wall Street
Here are today’s most compelling market narratives. $NTHI, $AMST, $MTVA, $AGYS, $INM, $CODX
NeOnc Technologies Gains Growing Institutional Support Ahead of Key Brain Cancer Clinical Milestones
NeOnc Technologies (NASDAQ:NTHI), a clinical-stage biotechnology company focused on treatments for central nervous system (CNS) cancers, has recently attracted growing attention from Wall Street analysts, institutional investors, and company insiders as it advances its pipeline of novel brain cancer therapies.
Traders are Piling into These Momentum Rockets
Among the standout movers is GCT Semiconductor (NYSE:GCTS), which surged to a fresh 52-week high of $2.54 after delivering a strong first quarter 2026 business update and financial report. At the same time, traders are rotating into biotech catalysts surrounding NeOnc Technologies (NASDAQ:NTHI), while shipping operator C3is (NASDAQ:CISS) posted explosive adjusted earnings growth amid exceptionally strong tanker market conditions. Meanwhile, AI and advertising technology names remained active after LiveRamp (NYSE:RAMP) announced a $2.5 billion acquisition agreement with Publicis Groupe. $GCTS, $NTHI, $CISS, $RAMP, $AIIO
The Spec Growth Trade is Alive
The speculative growth trade remains alive in 2026, with emerging companies across artificial intelligence, biotech, crypto infrastructure, gaming, and digital media aggressively pursuing expansion strategies aimed at capturing investor attention in some of the market’s hottest sectors. $AUUD, $NTHI, $PIII, $GEMI, $SNAL, $SLE, $FIG, $EDBL
Download the 24/7 Market News App here https://app.247mnn.com/ or on the App Store
These Catalysts are Triggering Massive Momentum
From enterprise AI clouds to breakthrough biotech catalysts, several emerging and mid-cap companies are capturing investor attention as transformative technologies accelerate commercialization and strategic partnerships deepen across industries. $XERI, $RXT, $NTHI, $GLE, $SOBR, $FLNC
Biotech’s Next Wave May Already be in Motion
The biotech and pharma sector is entering one of its most pivotal periods in years, where insider conviction, late-stage clinical wins, and platform technologies are converging to reshape both valuations and patient outcomes. From aggressive insider buying ahead of critical data to blockbuster Phase 3 readouts redefining entire therapeutic categories, the market is signaling that the next cycle of winners may already be taking shape. $NTHI, $ERNA, $LLY, $NVO, $REGN, $MRNA
Where Executives Are Doubling Down on Their Companies’ Fortunes
As market participants are sifting through data, one signal often cuts through the noise: insiders putting real money to work. Executives and strategic stakeholders have been accumulating shares in meaningful size, ranging from six-figure buys to billion-dollar commitments. While insider buying is never a guarantee of upside, it frequently reflects conviction rooted in operational visibility, upcoming catalysts, or perceived undervaluation. $NTHI, $RIVN, $SRAD, $NWBI, $FGBI
<
1
2
...
>
Compact View
Not available
Not available